Moreover, developing AD pathology biomarkers such as assays of amyloid-β, tau, and phosphorylated tau levels in the cerebrospinal fluid or blood plasma has been valuable in closing the gap between diagnosis during life and pathologic AD diagnosis [6, 31]. The gene discussed is MAPT; the disease is Alzheimer disease.